Amgen (Nasdaq: AMGN) has reported stronger-than-expected third-quarter results, driven by double-digit gains across several ...
Less than six months after ending a short-lived partnership, US telehealth firm Hims & Hers (Nasdaq: HIMS) and Danish ...
California-based Azalea Therapeutics, a biotech promising to redefine precision genomic medicines in vivo, has announced its ...
Novo Nordisk presented new data from the OASIS 4 Phase III trial that explored a variety of patients and hypotheses, adding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results